Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils

B N Cronstein, Y Molad, J Reibman, E Balakhane, R I Levin, G Weissmann, B N Cronstein, Y Molad, J Reibman, E Balakhane, R I Levin, G Weissmann

Abstract

Since colchicine-sensitive microtubules regulate the expression and topography of surface glycoproteins on a variety of cells, we sought evidence that colchicine interferes with neutrophil-endothelial interactions by altering the number and/or distribution of selectins on endothelial cells and neutrophils. Extremely low, prophylactic, concentrations of colchicine (IC50 = 3 nM) eliminated the E-selectin-mediated increment in endothelial adhesiveness for neutrophils in response to IL-1 (P < 0.001) or TNF alpha (P < 0.001) by changing the distribution, but not the number, of E-selectin molecules on the surface of the endothelial cells. Colchicine inhibited stimulated endothelial adhesiveness via its effects on microtubules since vinblastine, an agent which perturbs microtubule function by other mechanisms, diminished adhesiveness whereas the photoinactivated colchicine derivative gamma-lumicolchicine was inactive. Colchicine had no effect on cell viability. At higher, therapeutic, concentrations colchicine (IC50 = 300 nM, P < 0.001) also diminished the expression of L-selectin on the surface of neutrophils (but not lymphocytes) without affecting expression of the beta 2-integrin CD11b/CD18. In confirmation, L-selectin expression was strikingly reduced (relative to CD11b/CD18 expression) on neutrophils from two individuals who had ingested therapeutic doses of colchicine. These results suggest that colchicine may exert its prophylactic effects on cytokine-provoked inflammation by diminishing the qualitative expression of E-selectin on endothelium, and its therapeutic effects by diminishing the quantitative expression of L-selectin on neutrophils.

References

    1. Proc Natl Acad Sci U S A. 1973 Mar;70(3):844-8
    1. J Immunol. 1994 May 15;152(10):5060-9
    1. Proc Natl Acad Sci U S A. 1973 Oct;70(10):2916-20
    1. J Clin Invest. 1973 Nov;52(11):2745-56
    1. Ann N Y Acad Sci. 1975 Jun 30;253:455-69
    1. Adv Prostaglandin Thromboxane Res. 1976;1:105-10
    1. J Cell Biol. 1977 Apr;73(1):242-56
    1. Proc Natl Acad Sci U S A. 1977 Aug;74(8):3404-8
    1. J Cell Sci. 1981 Apr;48:181-91
    1. J Clin Invest. 1981 Oct;68(4):863-74
    1. Biochem Biophys Res Commun. 1981 Dec 15;103(3):1100-6
    1. J Immunol. 1983 Jan;130(1):38-44
    1. J Clin Invest. 1985 Nov;76(5):2003-11
    1. J Immunol. 1986 Feb 1;136(3):1027-32
    1. J Immunol. 1986 Mar 1;136(5):1680-7
    1. J Clin Invest. 1986 Sep;78(3):760-70
    1. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9238-42
    1. J Immunol. 1988 Sep 1;141(5):1665-9
    1. Science. 1989 Mar 3;243(4895):1160-5
    1. Science. 1989 Sep 15;245(4923):1238-41
    1. J Exp Med. 1990 Mar 1;171(3):715-27
    1. Proc Natl Acad Sci U S A. 1990 Mar;87(6):2244-8
    1. Science. 1990 Nov 23;250(4984):1132-5
    1. J Immunol. 1991 Feb 1;146(3):988-96
    1. J Clin Invest. 1991 Feb;87(2):609-18
    1. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2441-5
    1. J Clin Invest. 1991 Apr;87(4):1375-81
    1. Cell Immunol. 1991 Jan;132(1):201-14
    1. Inflammation. 1992 Feb;16(1):45-56
    1. Eur J Immunol. 1992 May;22(5):1279-86
    1. Arthritis Rheum. 1993 Feb;36(2):147-57
    1. J Exp Med. 1993 Mar 1;177(3):833-8
    1. J Biol Chem. 1993 Feb 25;268(6):3833-7
    1. J Clin Invest. 1993 Apr;91(4):1649-55
    1. J Clin Invest. 1993 Oct;92(4):1722-9
    1. Annu Rev Biochem. 1973;42:507-40

Source: PubMed

3
Suscribir